TABLE 2.
Characteristics of patients with advanced‐stage DLBCL and c‐HL scheduled to receive six cycles of R‐COMP‐DI and MBVD‐DI respectively
| Baseline characteristics | Total, n (%) | R‐COMP‐DI, n (%) | MBVD‐DI, n (%) |
|---|---|---|---|
| Patients | 81 | 53 | 28 |
| Age, years, median (range) | 50 (22–70) | 60 (29–70) | 40 (22–64) |
| <45 | 19 (23) | 6 (10) | 13 (46) |
| 45–54 | 28 (35) | 20 (38) | 8 (28) |
| 55–65 | 20 (25) | 16 (30) | 4 (16) |
| >65 | 14 (17) | 11 (22) | 3 (10) |
| Male sex | 44 (55) | 28 (52) | 16 (57) |
| Histological subtype | |||
| DLBCL | 53 (65) | 53 (100) | NA |
| Non‐germinal centre | 34 (65) | NA | |
| Germinal centre | 15 (30) | NA | |
| NOS | 4 (5) | NA | |
| c‐HL | 28 (35) | NA | 28 (100) |
| Nodular sclerosis | NA | 22 (78) | |
| Mixed cellularity | NA | 5 (18) | |
| Lymphocyte‐rich | NA | 1 (4) | |
| ECOG PS 0–2 | 71 (88) | 45 (85) | 26 (93) |
| ECOG PS 3 | 10 (12) | 8 (15) | 2 (7) |
| Disease stage | |||
| III | 44 (55) | 33 (62) | 11 (40) |
| IV | 37 (45) | 20 (38) | 17 (60) |
| Symptoms B | 54 (66) | 37 (69) | 17 (60) |
| Number of lymph node sites involved | |||
| Median, range | 6 (4–25) | 6 (4–25) | 6 (4–14) |
| Bulky disease | 39 (48) | 18 (34) | 21 (75) |
| Splenic involvement | 16 (20) | 10 (19) | 6 (21) |
| Extra‐nodal involvement a | 46 (57) | 28 (53) | 18 (64) |
| IPI ≥ 3 | 37 (45) | 37 (70) | NA |
| CNS‐IPI ≥ 4 | 13 (16) | 13 (24.5) | NA |
| IPS ≥ 3 | 17 (21) | NA | 17 (61) |
Note: Values are n (%) unless otherwise noted.
Abbreviations: c‐HL, classical Hodgkin lymphoma; CNS‐IPI, International Prognostic Index to assess the risk of central nervous system disease (including age >60 years, serum lactate dehydrogenase >normal, performance status >1, kidney or adrenal gland involvement 27 ); DI, dose intensified; DLBCL, diffuse large B‐cell lymphoma; ECOG PS, Eastern Cooperative Group Performance Status; IPI, International Prognostic Index (including age >60 years, Ann Arbor Stage III or IV, elevated serum lactate dehydrogenase, more than one extra‐nodal site involved); IPS, International Prognostic Score (including serum albumin <4 g/dl, haemoglobin <105 g/l, male sex, Ann Arbor Stage IV, age >45 years, white blood cell count >15× 109/l, lymphocyte count <0.6× 109/l); MBVD, Myocet™, bleomycin, vinblastine and dacarbazine; NA, not applicable; NOS, not otherwise specified; R‐COMP, rituximab, cyclophosphamide, Myocet™, vincristine and prednisone; Stage III, defined as multiple lymph node groups on both sides of the diaphragm; Stage IV, defined as multiple extra‐nodal sites or lymph nodes and extra‐nodal disease; Bulky disease, defined as lymph node mass with long axis >5 cm; Symptoms B, fever >38°C, drenching night sweats, and weight loss of >10% of body mass in the previous 6 months.
There were some patients in Stage III‐E.